Ontology highlight
ABSTRACT:
SUBMITTER: Aujla A
PROVIDER: S-EPMC6458768 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
Aujla Amandeep A Aujla Ravijot R Liu Delong D
Biomarker research 20190411
B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) frequently express CD19, CD20 and CD22 on the cell surfaces. Immunotherapeutic agents including antibodies and chimeric antigen receptor T cells are widely studied in clinical trials. Several antibody-drug conjugates (ADC) have been approved for clinical use (gemtuzumab ozogamicin in acute myeloid leukemia and brentuximab vedotin in Hodgkin lymphoma as well as CD30+ anaplastic large cell lymphoma). Inotuzumab ozogamicin (IN ...[more]